J. Kevin Buchi
Known title: DirectorCIK: 0001209726
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Benitec Biopharma shares fell 23.9% over four weeks. Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.
Transaction History
| AMRX | ▼ Sell | Gift | 20,445 | $0 | 9/17/2026 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 20,445 | $295K | 9/11/2026 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 168,573 | $2.9M | 8/11/2026 | View on chart |
| BNTC | ▼ Sell | Gift | 51,813 | $0 | 6/29/2026 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 34,819 | — | 5/7/2026 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 40,258 | — | 5/5/2025 | View on chart |
| BNTC | ▼ Sell | Gift | 103,626 | $0 | 3/12/2025 | View on chart |
| BNTC | ▼ Sell | Gift | 103,626 | $0 | 3/12/2025 | View on chart |
| AMRX | ▼ Sell | Gift | 262,072 | $0 | 3/10/2025 | View on chart |
| BNTC | ▲ Buy | Option Exercise | 51,813 | $200K | 2/27/2025 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 76,453 | — | 5/10/2024 | View on chart |
| BNTC | ▲ Buy | Open Market | 51,813 | — | 8/11/2023 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 80,128 | — | 5/10/2023 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 35,406 | — | 5/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
AMRX Gains Fair Value Bump After Analyst Support for New Launches
Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.
AMRX Gains Fair Value Bump After Analyst Support for New Launches. Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.